News

Qiagen and Bayer team up for CDx
Enlarge image

PharmaNetherlandsGermany

Qiagen and Bayer team up for CDx

26.10.2012 - Pharma giant Bayer Healthcare and diagnostics specialist Qiagen N.V.
have forged an alliance in the field of companion diagnostics (CDx).

Initially, the joint efforts will concentrate on several types of solid tumours. But the agreement also lays the groundwork for a strong partnership in creating future companion diagnostics both inside and outside of oncology. The targeted companion diagnostics will be designed to run on Qiagen’s QIAsymphony line of automated instruments. In addition, the partners said that they will collaborate on developing technologies for patient profiling, which may result on research-use-only products for exploratory and translational medicine, said Qiagen.

„As healthcare providers increasingly select the right drugs based on each individual's genomic information, the treatment of cancer is undergoing a revolution," said Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and Member of the Executive Committee of Qiagen. Companion diagnostics guide treatment decisions with medications for cancers or other diseases by unlocking molecular information from each patient's tumour genome. „This helps to design more efficient clinical trials and to increase the overall probability of therapeutic success for patients suffering from cancer," said Andreas Busch, Head of Global Drug Discovery and Member of the Executive Committee of Bayer HealthCare.

Qiagen has more than 15 companion diagnostic collaborations ongoing with pharmaceutical and biotech companies. A major milestone was reached in July, on FDA approval of Therascreen RGQ PCR Kit. The companion diagnostic is used to screen for those metastatic colorectal cancer patients who most likely respond to therapy with Erbitux (cetuximab).

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/qiagen-and-bayer-team-up-for-cdx.html

Personalised MedicineNetherlandsBelgiumSpain

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BAVARIAN NORDIC (D)44.62 EUR12.34%
  • MOLOGEN (D)5.20 EUR7.00%
  • BRITISH TECHNOLOGY GROUP (UK)686.00 GBP6.94%

FLOP

  • CYTOS (CH)0.50 CHF-9.09%
  • NOVACYT (F)4.99 EUR-6.90%
  • EPIGENOMICS (D)5.12 EUR-5.19%

TOP

  • DBV Technologies (F)54.26 EUR26.8%
  • VERONA PHARMA (UK)5.10 GBP17.2%
  • MEDIGENE (D)9.72 EUR16.0%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.80 EUR-26.9%
  • NORDIC NANOVECTOR (N)25.50 NOK-25.9%

TOP

  • ADOCIA (F)66.29 EUR388.1%
  • 4SC (D)4.90 EUR375.7%
  • VERONA PHARMA (UK)5.10 GBP314.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.00 SEK-70.1%
  • NEOVACS (F)1.14 EUR-69.1%

No liability assumed, Date: 02.07.2015